In This Article:
As European markets navigate a landscape marked by mixed economic signals and trade-related uncertainties, the pan-European STOXX Europe 600 Index has managed to break a two-week losing streak, buoyed by hopes of increased government spending. Amidst this backdrop, growth companies with high insider ownership are often seen as appealing investments due to their potential for strong alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Elicera Therapeutics (OM:ELIC) | 27.8% | 97.2% |
| Pharma Mar (BME:PHM) | 11.8% | 40.8% |
| Vow (OB:VOW) | 13.1% | 111.2% |
| CD Projekt (WSE:CDR) | 29.7% | 39.1% |
| Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
| Devyser Diagnostics (OM:DVYSR) | 35.6% | 94.7% |
| Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
| Ortoma (OM:ORT B) | 27.7% | 68.6% |
| Nordic Halibut (OB:NOHAL) | 29.8% | 56.3% |
| Circus (XTRA:CA1) | 26% | 51.4% |
Here we highlight a subset of our preferred stocks from the screener.
OCI
Simply Wall St Growth Rating: ★★★★☆☆
Overview: OCI N.V. is a company that produces and distributes hydrogen-based and natural gas-based products for agricultural, transportation, and industrial sectors, with a market cap of €2.32 billion.
Operations: The company's revenue segments include $976.50 million from Nitrogen EU.
Insider Ownership: 38.9%
OCI N.V. shows potential as a growth company with high insider ownership in Europe. Despite being dropped from the FTSE All-World Index, OCI anticipates profitability and above-average market profit growth over the next three years. Revenue is expected to grow at 14.3% annually, outpacing the Dutch market's 7.9%. The company plans extraordinary distributions of up to $1 billion in Q2 2025, indicating strong shareholder returns despite a forecasted low return on equity at 4%.
BICO Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BICO Group AB (publ) is a bioconvergence company operating in North America, Europe, Asia, and internationally with a market cap of SEK2.71 billion.
Operations: The company's revenue is segmented into Bioprinting (SEK369.30 million), Lab Automation (SEK571.60 million), and Life Science Solutions (SEK1.01 billion).
Insider Ownership: 25.2%
BICO Group's revenue is forecast to grow at 7.2% annually, outpacing the Swedish market's 0.8%, with earnings expected to rise by 54.46% per year, signaling strong growth potential despite a volatile share price recently. The company reported significant improvement in net income for Q4 2024, with SEK 346.8 million compared to a prior loss of SEK 561.6 million, though annual sales slightly decreased to SEK 1.95 billion from SEK 2 billion previously.